RecruitingPhase 3NCT06973304

A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome

Studying Short bowel syndrome

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Takeda
Principal Investigator: Study Director
Takeda
Intervention: Teduglutide(drug)
Enrollment: 13 enrolled
Eligibility: 18 years · All sexes
Timeline: 2025 – 2027

Study locations (4)

Beijing Tsinghua Changgung Hospital, Changping, Beijing Municipality, China
Peking Union Medical College Hospital, Dongcheng, Beijing Municipality, China
Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, China
Zhongshan Hospital, Xiamen University, Siming, Xiamen, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06973304 on ClinicalTrials.gov

Other trials for Short bowel syndrome

Additional recruiting or active studies for the same condition.

See all trials for Short bowel syndrome →

← Back to all trials